Last reviewed · How we verify

NCT03433144: TXA-OMFS

The Effects of Tranexamic Acid on Blood Loss During Orthognathic Surgery

Withdrawn Phase 4 Last updated 6 August 2021
What this trial tests

Phase 4 trial testing Tranexamic Acid Injectable Solution in Tranexamic Acid. Withdrawn.

Timeline
1 June 2018
Primary endpoint
1 February 2019
6 July 2020

Quick facts

Lead sponsorNick Emanuele
PhasePhase 4
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Start date1 June 2018
Primary completion1 February 2019
Estimated completion6 July 2020
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Nick Emanuele

Who can join

Adults 16 to 65, any sex, with Tranexamic Acid or Orthognathic Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study seeks to answer the question: Does a single pre-operative dose of tranexamic acid have a statistically significant reduction in blood loss during orthognathic surgery? If it does, this drug may begin to be used routinely during orthognathic surgery to reduce blood loss in our patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Tranexamic Acid Injectable Solution

Trials testing the same drug.

Other recruiting trials for Tranexamic Acid

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03433144.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing